NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017
United States
614-793-7500
http://www.navidea.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Jed A. LatkinCEO, COO, CFO & Director639.88kN/A1974
Dr. Michael Stanley Rosol Ph.D.Chief Medical Officer222.6kN/A1968
Erika GibsonDirector of Fin. & Admin.N/AN/AN/A
Mr. William J. ReganChief Compliance OfficerN/AN/A1952
Ms. Sharon CorreiaSr. Director of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Corporate Governance

Navidea Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.